15,259 Shares in Lantheus Holdings, Inc. (NASDAQ:LNTH) Bought by New Age Alpha Advisors LLC

New Age Alpha Advisors LLC bought a new stake in Lantheus Holdings, Inc. (NASDAQ:LNTH) in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm bought 15,259 shares of the medical equipment provider’s stock, valued at approximately $1,365,000.

A number of other institutional investors have also recently added to or reduced their stakes in LNTH. Cerity Partners LLC increased its position in shares of Lantheus by 19.8% in the third quarter. Cerity Partners LLC now owns 11,897 shares of the medical equipment provider’s stock valued at $1,306,000 after buying an additional 1,966 shares in the last quarter. Glenmede Trust Co. NA purchased a new position in Lantheus during the 3rd quarter valued at about $540,000. CreativeOne Wealth LLC raised its position in Lantheus by 10.7% during the third quarter. CreativeOne Wealth LLC now owns 5,167 shares of the medical equipment provider’s stock worth $567,000 after acquiring an additional 499 shares during the last quarter. Captrust Financial Advisors grew its position in shares of Lantheus by 33.2% in the third quarter. Captrust Financial Advisors now owns 36,091 shares of the medical equipment provider’s stock valued at $3,961,000 after purchasing an additional 9,005 shares during the last quarter. Finally, HighTower Advisors LLC purchased a new position in shares of Lantheus during the 3rd quarter worth approximately $607,000. Hedge funds and other institutional investors own 99.06% of the company’s stock.

Lantheus Trading Down 0.9 %

Shares of NASDAQ:LNTH opened at $96.16 on Monday. Lantheus Holdings, Inc. has a 12-month low of $58.16 and a 12-month high of $126.89. The stock’s 50-day moving average price is $93.21 and its two-hundred day moving average price is $96.38. The firm has a market cap of $6.59 billion, a price-to-earnings ratio of 16.00 and a beta of 0.38.

Lantheus (NASDAQ:LNTH) last released its earnings results on Thursday, February 27th. The medical equipment provider reported $1.34 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.57 by ($0.23). Lantheus had a return on equity of 44.29% and a net margin of 28.57%. The company had revenue of $391.11 million during the quarter, compared to analyst estimates of $376.61 million. As a group, research analysts forecast that Lantheus Holdings, Inc. will post 6.01 earnings per share for the current fiscal year.

Insider Activity

In other news, Director Mary Anne Heino sold 53,107 shares of the business’s stock in a transaction dated Monday, March 3rd. The stock was sold at an average price of $94.35, for a total transaction of $5,010,645.45. Following the completion of the sale, the director now owns 440,399 shares in the company, valued at approximately $41,551,645.65. The trade was a 10.76 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, Director James H. Thrall sold 1,000 shares of the stock in a transaction that occurred on Wednesday, January 15th. The stock was sold at an average price of $94.76, for a total transaction of $94,760.00. Following the sale, the director now directly owns 33,207 shares of the company’s stock, valued at approximately $3,146,695.32. This trade represents a 2.92 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 64,109 shares of company stock valued at $6,110,806 in the last ninety days. Company insiders own 1.50% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities research analysts have commented on the company. The Goldman Sachs Group initiated coverage on Lantheus in a report on Wednesday, December 18th. They set a “buy” rating and a $143.00 target price on the stock. B. Riley decreased their price objective on Lantheus from $127.00 to $122.00 and set a “buy” rating on the stock in a research note on Friday, March 21st. Truist Financial boosted their target price on shares of Lantheus from $120.00 to $127.00 and gave the company a “buy” rating in a research note on Thursday, February 27th. Finally, JMP Securities reaffirmed a “market outperform” rating and set a $112.00 price target on shares of Lantheus in a research note on Tuesday, January 14th. One investment analyst has rated the stock with a hold rating and seven have assigned a buy rating to the company. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $129.43.

About Lantheus

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.